Technical Analysis for GH - Guardant Health, Inc.

Grade Last Price % Change Price Change
B 156.84 1.19% 1.84
GH closed up 1.19 percent on Tuesday, April 13, 2021, on 60 percent of normal volume.
Earnings due: May 5
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat
Historical GH trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 1.19%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.19%
Overbought Stochastic Strength 1.19%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.21%
Overbought Stochastic Strength -0.21%
Narrow Range Bar Range Contraction -1.68%
NR7 Range Contraction -1.68%
Upper Bollinger Band Walk Strength -1.68%
Multiple of Ten Bearish Other -1.68%
Inside Day Range Contraction -1.68%
Older End-of-Day Signals for GH ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% about 8 hours ago
60 Minute Opening Range Breakdown about 9 hours ago
10 DMA Resistance about 11 hours ago
Up 2% about 11 hours ago
Fell Below 10 DMA about 11 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Guardant Health, Inc. Description

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biopharmaceutical Cancer Clinical Development Disease Oncology Telemedicine Telehealth Lab Testing Precision Medicine Blood Test Blood Tests Reimbursement Biopsy Healthcare Costs

Is GH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 181.07
52 Week Low 67.31
Average Volume 927,115
200-Day Moving Average 119.73
50-Day Moving Average 152.30
20-Day Moving Average 148.77
10-Day Moving Average 156.40
Average True Range 7.11
ADX 17.42
+DI 25.06
-DI 23.34
Chandelier Exit (Long, 3 ATRs ) 143.15
Chandelier Exit (Short, 3 ATRs ) 150.81
Upper Bollinger Band 166.37
Lower Bollinger Band 131.16
Percent B (%b) 0.73
BandWidth 23.67
MACD Line 2.97
MACD Signal Line 1.51
MACD Histogram 1.4617
Fundamentals Value
Market Cap 15.68 Billion
Num Shares 100 Million
EPS -1.28
Price-to-Earnings (P/E) Ratio -122.44
Price-to-Sales 41.99
Price-to-Book 10.86
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 165.45
Resistance 3 (R3) 165.17 162.03 164.02
Resistance 2 (R2) 162.03 159.83 162.17 163.54
Resistance 1 (R1) 159.43 158.48 160.73 159.71 163.06
Pivot Point 156.29 156.29 156.94 156.43 156.29
Support 1 (S1) 153.69 154.09 154.99 153.97 150.62
Support 2 (S2) 150.55 152.74 150.69 150.14
Support 3 (S3) 147.95 150.55 149.67
Support 4 (S4) 148.23